Adakveo (crizanlizumab-tmca) is an intravenous humanized monoclonal antibody that binds to P-selectin. P-selectin is an adhesion molecule expressed on vascular endothelial cells and platelets and is a key modulator in the vaso-occlusive process. The inhibition of P-selectin is believed to reduce sickle red blood cell adhesion, thereby improving blood flow and minimizing vaso-…
Publications
Hayes Publications are available through the Hayes Knowledge Center, a portal to world-class research and unbiased analyses on the clinical, financial, and risk impacts of emerging, controversial, and disruptive healthcare technologies.Every Hayes publication is developed by multidisciplinary teams of clinicians and scientists using rigorous methods grounded in internally recognized standards for systematic review and Health Technology Assessment. Learn more about these evidence resources and see sample titles below.
See below for some of our recent publications.
Adakveo (Crizanlizumab-tmca) for Sickle Cell Disease
Adakveo (crizanlizumab-tmca) is an intravenous humanized monoclonal antibody that binds to P-selectin. P-selectin is an adhesion molecule expressed on vascular endothelial cells and platelets and is a key modulator in the vaso-occlusive process. The inhibition of P-selectin is believed to reduce sickle red blood cell adhesion, thereby improving blood flow and minimizing vaso-…
Deep Brain Stimulation of the Anterior Nucleus of the Thalamus for Treatment of Refractory Epilepsy
Health Problem: Epilepsy is one of the most common neurological disorders in the United States and has a prevalence of approximately 3 million adults and 470,000 children. Management generally involves treatment with antiepileptic drugs (AEDs), but for approximately 30% of patients, seizures will remain uncontrolled by medical therapy. In the…
Transcutaneous Bone–Anchored Hearing Aids
Health Problem: In the United States, it is estimated that 48 million adults have some type of hearing loss. Hearing loss can be broadly classified as sensorineural (inner ear), conductive (external and middle ear), or mixed.
Technology Description: Transcutaneous bone–anchored hearing…
Ruzurgi (Amifampridine) for Pediatric Lambert-Eaton Myasthenic Syndrome
Ruzurgi (amifampridine, base form) is an oral drug intended for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in children aged 6 to < 17 years. Ruzurgi is a voltage-gated potassium channel inhibitor that prolongs the depolarization of the pre-synaptic cell membrane, allowing for enhanced calcium influx into the neuron. This facilitates increased release of acetylc...
Ruzurgi (Amifampridine) for Pediatric Lambert-Eaton Myasthenic Syndrome
Ruzurgi (amifampridine, base form) is an oral drug intended for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in children aged 6 to < 17 years. Ruzurgi is a voltage-gated potassium channel inhibitor that prolongs the depolarization of the pre-synaptic cell membrane, allowing for enhanced calcium influx into the neuron. This facilitates increased release of acetylc...
Esketamine (Spravato) for Treatment Resistant Major Depressive Disorder
Health Problem: Major depressive disorder (MDD), a serious and life-threatening condition, is one of the most common mental disorders in the United States and a leading cause of disability worldwide. MDD is a chronic disease associated with high rates of morbidity and excess mortality. Approximately 30% to 40% of patients fail to respond to f…
Firdapse (Amifampridine Phosphate)
Firdapse (amifampridine phosphate) is an oral voltage-gated potassium channel inhibitor for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. Firdapse increases the release of acetylcholine from nerve cells, prolonging the depolarization of the pre-synaptic cell membrane and allowing for enhanced calcium influx into the neuron. This, in turn, fa…
Firdapse (Amifampridine Phosphate)
Firdapse (amifampridine phosphate) is an oral voltage-gated potassium channel inhibitor for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. Firdapse increases the release of acetylcholine from nerve cells, prolonging the depolarization of the pre-synaptic cell membrane and allowing for enhanced calcium influx into the neuron. This, in turn, fa…
Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis Resulting from Peritoneal Mesothelioma
Health Problem: Peritoneal mesothelioma (PM) is a rare primary tumor affecting the serosal (watery) lining of the peritoneum.
Technology Description: Hyperthermic intraperitoneal chemotherapy (HIPC) is used as an adjunct to surgery for the treatment of peritoneal carcinomatosis (PC) du…